With extensive bridging fibrosis, cirrhosis ... perisinusoidal fibrosis is often associated with active lesions of steatohepatitis as described earlier, zone 3 perisinusoidal fibrosis in the ...

Unlike LPA1 receptor antagonists under clinical investigation, PAT-409 has demonstrated efficacy in rodent models of nonalcoholic steatohepatitis. PAT-409 also reduced fibrosis in a rat model of ...

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

Gilead's top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis ... selonsertib in patients with bridging fibrosis due to NASH and the ...

Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC ...